otolaryngology-2017-scientifictracks-abstracts

3 / 14

Page 18
Notes:
conferenceseries.com
Volume 7, Issue 5 (Suppl) Otolaryngol
ISSN: 2161-119X Otolaryngol, an open access journal Otolaryngology 2017
October 18-19, 2017
October 18-19, 2017 Dubai, UAE
4th International Conference on
Rhinology and Otology
Effects of Bifidobacterium breve feeding strategy and delivery modes on experimental allergic rhinitis
mice
Yang Xu, Ren J, Yang F L, Lv D, Hung S, Zhang J, Lin P, Liu S X, Zhang N and Bachert C
Sichuan University, China
Background: Di erent delivery modes may a ect the susceptibility to allergic diseases. It is still unknown whether early
intervention with probiotics would counteract this e ect.
Objectives: e e ect of di erent delivery modes on immune status and nasal symptoms was investigated on established
allergic rhinitis (AR) mouse model. In addition, the immunoregulatory e ects and mechanisms of di erent feeding manners
with Bi dobacterium breve were examined.
Methods: Live lyophilized B. breve was orally administered to BALB/c mice born via vaginal delivery (VD) or cesarean delivery
(CD) for 8 consecutive weeks, a er which they were sensitized by ovalbumin (OVA) to establish experimental AR. Nasal
symptoms, serum immunoglobulins, cytokines, splenic percentages of CD4+CD25+Foxp3+ regulatory T(Treg) cells and nasal
eosinophil in ltration were evaluated.
Results: Compared with VD mice, mice delivered via CD demonstrated more serious nasal symptoms, higher concentrations
of OVA-speci c immunoglobulin (Ig) E, more nasal eosinophil and lower percentages of splenic CD4+CD25+Foxp3+Treg cells
a er establishing experimental AR. ese parameters were reversed by administering B. breves shortly a er birth. However, the
e ect of B. breve did not di er between di erent delivery modes.
Conclusion: CD aggravates the nasal symptoms of AR mice compared to VD. is is the rst report that oral administration of
B. breve shortly a er birth can signi cantly alleviate the symptoms of AR mice born via both deliveries, probably via activation
of the regulatory capacity of CD4+CD25+Foxp3+Treg cells.
Biography
Yang Xu is currently pursuing his PhD in West China School of Medicine, Sichuan University, China. He focuses on scientific research about rhinology and otology.
Yang Xu et al., Otolaryngol 2017, 7:5 (Suppl)
DOI: 10.4172/2161-119X-C1-022